Cargando…
HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor?
Autores principales: | Costentin, Charlotte E., Nahon, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283026/ https://www.ncbi.nlm.nih.gov/pubmed/34308325 http://dx.doi.org/10.1016/j.jhepr.2021.100320 |
Ejemplares similares
-
Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication
por: Nahon, Pierre, et al.
Publicado: (2019) -
Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control
por: Nahon, Pierre, et al.
Publicado: (2021) -
Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021) -
Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
por: Morisco, Filomena, et al.
Publicado: (2021) -
Evaluation of fibrosis in cirrhotic elderly patients with HCC
por: Pesce, A, et al.
Publicado: (2011)